DXC TECHNOLOGY SERVICIOS ESPANA SL

Their core work

DXC Technology is a large global IT services company that brings enterprise-grade data infrastructure, security architecture, and AI capabilities into health research consortia. In H2020 projects, they serve as the technical backbone — designing the systems that allow sensitive clinical and genomic data to flow safely between hospitals, universities, and research institutions. Their specific contributions include implementing healthcare data interoperability standards, building privacy-preserving and ethics-compliant data pipelines, and deploying federated learning frameworks that allow AI models to train on distributed clinical datasets without centralizing patient data. They are not a research lab — they are the company that makes large-scale health data research technically feasible and legally sound.

What they specialise in

How they've shifted over time

DXC's early H2020 engagement (PERSIST, 2020) was centered on patient-centric data infrastructure: building interoperable systems for cancer survivorship care while satisfying privacy and ethics requirements — essentially data plumbing with compliance guardrails. Their second project (GenoMed4ALL, 2021) marks a shift toward active AI development: federated learning and multi-omics processing require algorithmic sophistication beyond infrastructure work. The trajectory is clear — DXC is moving from being a data governance provider to becoming a contributor to the AI models themselves, specifically in the privacy-preserving distributed learning space.

DXC is moving from healthcare data compliance infrastructure toward privacy-preserving federated AI, positioning themselves as a technical partner for any consortium that needs to train models on sensitive distributed health data without centralizing it.

How they like to work

DXC participates exclusively as a consortium partner — they have never coordinated an H2020 project, which is consistent with how large IT services companies engage in public research: contributing defined technical workpackages rather than leading scientific direction. Their involvement in consortia averaging over 20 partners across 16 countries per project suggests they are experienced in large, multi-institution environments and deliver against specification rather than driving the research agenda. Expect reliable, structured delivery on data and technology workpackages, not scientific initiative.

From just 2 projects, DXC has connected with 41 unique partners across 16 countries — indicating involvement in large pan-European health research consortia with diverse national health systems and academic institutions. This breadth reflects the scope of the H2020 health pillar projects they joined, not a cultivated bilateral network.

What sets them apart

DXC Technology occupies a rare position in health research consortia: an enterprise IT services company with the scale to handle production-grade data infrastructure, the compliance expertise to satisfy GDPR and medical ethics boards, and the emerging technical depth to contribute to federated AI development. Most private companies in EU health projects are either small specialized tech firms or domain-specific health IT vendors — DXC brings industrial-scale reliability and breadth of capability that smaller partners cannot match. For consortium coordinators assembling a team to work with real patient data at scale, DXC reduces the risk of technical and regulatory failure.

Highlights from their portfolio

• PERSIST
  Their entry point into H2020 and the only project with confirmed EC funding (EUR 315,775), directly addressing cancer survivorship with Big Data and AI while explicitly tackling the privacy and ethics challenges that block most health data projects.
• GenoMed4ALL
  Represents a significant technical step up — applying federated learning to multi-omics data in haematological diseases, one of the most technically demanding combinations in current health AI research.